161 related articles for article (PubMed ID: 18075315)
21. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
[TBL] [Abstract][Full Text] [Related]
22. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.
Josefsberg Ben-Yehoshua L; Beider K; Shimoni A; Ostrovsky O; Samookh M; Peled A; Nagler A
PLoS One; 2012; 7(4):e33856. PubMed ID: 22558078
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
[TBL] [Abstract][Full Text] [Related]
24. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
[TBL] [Abstract][Full Text] [Related]
25. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
[TBL] [Abstract][Full Text] [Related]
26. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
27. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM; Gianella-Borradori A
Expert Opin Investig Drugs; 2005 Apr; 14(4):457-77. PubMed ID: 15882121
[TBL] [Abstract][Full Text] [Related]
28. Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension.
Planchais S; Glab N; Tréhin C; Perennes C; Bureau JM; Meijer L; Bergounioux C
Plant J; 1997 Jul; 12(1):191-202. PubMed ID: 9263460
[TBL] [Abstract][Full Text] [Related]
29. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Iurisci I; Filipski E; Reinhardt J; Bach S; Gianella-Borradori A; Iacobelli S; Meijer L; Lévi F
Cancer Res; 2006 Nov; 66(22):10720-8. PubMed ID: 17108108
[TBL] [Abstract][Full Text] [Related]
30. Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Thomas H
Anticancer Res; 2007; 27(1A):273-8. PubMed ID: 17352243
[TBL] [Abstract][Full Text] [Related]
31. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
Le Tourneau C; Faivre S; Laurence V; Delbaldo C; Vera K; Girre V; Chiao J; Armour S; Frame S; Green SR; Gianella-Borradori A; Diéras V; Raymond E
Eur J Cancer; 2010 Dec; 46(18):3243-50. PubMed ID: 20822897
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis.
Rossi AG; Sawatzky DA; Walker A; Ward C; Sheldrake TA; Riley NA; Caldicott A; Martinez-Losa M; Walker TR; Duffin R; Gray M; Crescenzi E; Martin MC; Brady HJ; Savill JS; Dransfield I; Haslett C
Nat Med; 2006 Sep; 12(9):1056-64. PubMed ID: 16951685
[TBL] [Abstract][Full Text] [Related]
33. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
Benson C; White J; De Bono J; O'Donnell A; Raynaud F; Cruickshank C; McGrath H; Walton M; Workman P; Kaye S; Cassidy J; Gianella-Borradori A; Judson I; Twelves C
Br J Cancer; 2007 Jan; 96(1):29-37. PubMed ID: 17179992
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of autophagy by 3-MA potentiates purvalanol-induced apoptosis in Bax deficient HCT 116 colon cancer cells.
Coker-Gurkan A; Arisan ED; Obakan P; Guvenir E; Unsal NP
Exp Cell Res; 2014 Oct; 328(1):87-98. PubMed ID: 25088259
[TBL] [Abstract][Full Text] [Related]
36. [Antiproliferative effect of bcl-2 gene does not concern the control of mitotic events].
Neliudova AM; Brichkina AI; Rukhlova MP; Aksenov ND; Pospelova TV
Tsitologiia; 2004; 46(3):257-67. PubMed ID: 15214171
[TBL] [Abstract][Full Text] [Related]
37. Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat.
Pezzotta A; Mister M; Monteferrante G; Cassis L; Azzollini N; Aiello S; Satta M; Benigni A; Remuzzi G; Noris M
Transplantation; 2008 May; 85(10):1476-82. PubMed ID: 18497689
[TBL] [Abstract][Full Text] [Related]
38. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
Nutley BP; Raynaud FI; Wilson SC; Fischer PM; Hayes A; Goddard PM; McClue SJ; Jarman M; Lane DP; Workman P
Mol Cancer Ther; 2005 Jan; 4(1):125-39. PubMed ID: 15657360
[TBL] [Abstract][Full Text] [Related]
39. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor.
Liu NA; Jiang H; Ben-Shlomo A; Wawrowsky K; Fan XM; Lin S; Melmed S
Proc Natl Acad Sci U S A; 2011 May; 108(20):8414-9. PubMed ID: 21536883
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
